On the contrary, patients treated with an anti-TNF antibody or an anti-IL-6 antibodies exhibit reduced levels of inflammatory markers such as IL-6, hepcidin, and/or C-reactive protein, correlating with improvement in anemia related to autoimmune inflammatory conditions (43). This evidence concerns the gene IL6 and anemia (phenotype).